Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)

2016 ESMO Congress
Tweet this page

Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)